Meet us in booth #426!


PEGS: the Essential Protein Engineering Summit, is the industry’s preeminent event that inspires accelerated biotherapeutic protein drug development. PEGS Boston 2019 will host more than 400 lectures, panels, tutorials and round-table discussions, along with 150+ exhibitors, and 300 research posters on display in the exhibit hall. The speaker lineup includes world-renowned experts, visionaries, and influencers from top pharma, biotech, academic, and government institutions.
 
For more information, visit https://www.pegsummit.com/.
 

Presentations

Difficult-to-Express Proteins - Overcoming Expression Challenges Track
Tuesday, April 9 | 3:05-3:35pm

GS Xceed® Gene Expression Toolbox: Overview and the Introduction of New Tools
Peter O'Callaghan, PhD, Principal Scientist, R&D

In this presentation, we will share an overview of the GS Xceed® Gene expression toolbox will be presented with a focus on new tools that have recently been added. Alongside this some new in-house research will be presented showing the benefit of applying control circuits to boost protein expression.

Immunogenicity Assessment and Regulatory Approval of Biologics Track
Wednesday, April 10 | 12:25-12:55

The Role of Product and Process-Related Impurities in the Innate Immune Response to Biotherapeutic Proteins
Noel Smith, PhD, Principal Group Leader, Applied Protein Services

Immunogenicity is a common problem for biotherapeutic proteins and can impact both efficacy and safety. Human in vitro assays are now routinely used during early development to assess the risk of a biotherapeutic protein inducing both an innate and adaptive immune response. This presentation will focus on the use of highly sensitive human primary cell assays for the assessment of product and process-related impurities that may contribute to driving an unwanted immune response.

Poster presentation

Utilising GS piggyBac™ transposon technology to enhance the performance of the Lonza GS Gene Expression System® in stable CHO pool construction
Peter O'Callaghan, PhD, Principal Scientist, R&D

The construction of stable Chinese hamster ovary (CHO) cell lines making recombinant therapeutic proteins is usually achieved by randomly integrating the expression vector into the CHO genome. As vector integration is achieved at random DNA break points, a large number of the resulting clones will have integrated the plasmid at sites of poor gene expression, leading to a low efficiency of cell line construction. Transposase technology can substantially improve the cell line construction process by targeting vector integration to sites of open chromatin where expression is likely to be high. The leading piggyBac™ system uses a transposase capable of integrating large DNA cargoes (<300Kb) at TTAA sites within accessible chromatin in a wide range of host cell types. In this work, we demonstrate how the hyperactive super PiggyBac™ variant can be combined with the Lonza GS Gene Expression System® to create stable CHO pools with improved expression of a challenging monoclonal antibody (mAb).  With only minimal changes to the Lonza GS Gene Expression System® vectors and processes it is possible to harness the power of transposases to generate high performing pools for material supply.


Contact us to schedule a meeting with us at PEGS Boston.

 

By submitting your data through this form, you confirm that you are above the age of 18, that you have read and understood the Privacy Policy, and that you agree to the collection, use and processing of your Personal Information by Lonza in accordance with said policy.